Xcout IntelBioAge Labs, Inc. competitors & alternatives
The 12 closest competitors and alternatives to BioAge Labs, Inc. among biotech companies — ranked by similarity to what BioAge Labs, Inc. actually does, not by market-cap band.
Subscribe to see BioAge Labs, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BioAge Labs, Inc. at a glance
BioAge Labs, Inc. is a biotech company headquartered in Emeryville, United States. It is publicly listed (BIOA) with a market capitalisation of $356.9M. Xcout tracks 23 named people at BioAge Labs, Inc., including Dov A. Goldstein (Chief Financial Officer).
BioAge Labs, Inc. leadership
- Dov A. GoldsteinChief Financial Officer
- Paul D. RubinChief Medical Officer & Executive Vice President of Research
- Ann C. NealeChief Development Officer
- Peng LeongChief Business Officer & Therapeutic Area Head of Brain Aging
- SullivanChief Strategy Officer
- Kristen FortneyCo-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director
17 more named people on record for BioAge Labs, Inc., with roles, board committees and tenure — see the full roster →
BioAge Labs, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $194.4M | 13 named | |
| Series C | $90M | 12 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 BioAge Labs, Inc. competitors
Ranked by semantic similarity — how close each company is to BioAge Labs, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Spring Discovery (also known as Spring Science) is a biotechnology research company founded in 2017 and based in San Carlos, California. The company focuses on therapeutics and drug discovery targeting age-related diseases.
Similar biotech company
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Similar biotech company
Biophytis is a clinical-stage biotechnology company that develops transformative therapies to impact longevity, slow aging, and improve sustainable health. The company utilizes a research platform to discover new drug candidates, with its lead candidate BIO101 being evaluated for the treatment of conditions such as sarcopenia and obesity.
Biotechnology
Carmot Therapeutics, Inc. is a biopharmaceutical company headquartered in Berkeley, California, focused on discovering and developing innovative treatments for metabolic diseases and obesity.
Health & Life Sciences
Deciduous Therapeutics, Inc. is a biotechnology startup located in San Francisco, California, focused on developing novel therapeutics targeting aging and immune dysfunction.
Biotechnology
Gordian Biotechnology is a biotechnology research company headquartered in South San Francisco, California. The company focuses on curing age-related diseases through in vivo target discovery and functional genomics platforms.
Similar biotech company
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Biotechnology
BridGene Biosciences, Inc. is a biotechnology company headquartered in San Jose, California, pioneering next-generation chemoproteomics through its IMTAC platform. The company is focused on discovering and developing innovative small molecule drugs for high-value targets.
Biotechnology
Rejuvenate Biomed is an independent research and development biotechnology company spun out from the Janssen Pharmaceutical companies of Johnson & Johnson. Headquartered in Diepenbeek in the Flemish Region of Belgium, the company focuses on longevity research to keep people healthy longer. It also maintains a presence in Cambridge, Massachusetts.
Biotechnology
Metabolic Solutions Development Company is a private biotechnology and drug discovery company founded in 2006. The firm focuses on investigating novel molecular targets and developing therapeutics to treat diabetes, metabolic syndrome, and related conditions.
Similar biotech company
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Similar biotech company
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BioAge Labs, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BioAge Labs, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →